Your browser doesn't support javascript.
loading
Towards Allograft Longevity: Leveraging Omics Technologies to Improve Heart Transplant Outcomes.
Truby, Lauren K; Maamari, Dimitri; Saha, Amit; Farr, Maryjane; Abdulrahim, Jawan; Billia, Filio; Peltz, Matthias; Khush, Kiran K; Wang, Thomas J.
Afiliación
  • Truby LK; University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA. lauren.truby@utsouthwestern.edu.
  • Maamari D; University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
  • Saha A; Broad Institute of MIT and Harvard, Cambridge, MA, USA.
  • Farr M; University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
  • Abdulrahim J; University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
  • Billia F; Duke Molecular Physiology Institute, Durham, NC, USA.
  • Peltz M; University Health Network, Toronto, ON, Canada.
  • Khush KK; University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX, 75390, USA.
  • Wang TJ; Stanford University Medical Center, Palo Alto, CA, USA.
Curr Heart Fail Rep ; 20(6): 493-503, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37966542
PURPOSE OF REVIEW: Heart transplantation (HT) remains the optimal therapy for patients living with end-stage heart disease. Despite recent improvements in peri-transplant management, the median survival after HT has remained relatively static, and complications of HT, including infection, rejection, and allograft dysfunction, continue to impact quality of life and long-term survival. RECENT FINDINGS: Omics technologies are becoming increasingly accessible and can identify novel biomarkers for, and reveal the underlying biology of, several disease states. While some technologies, such as gene expression profiling (GEP) and donor-derived cell-free DNA (dd-cfDNA), are routinely used in the clinical care of HT recipients, a number of emerging platforms, including pharmacogenomics, proteomics, and metabolomics, hold great potential for identifying biomarkers to aid in the diagnosis and management of post-transplant complications. Omics-based assays can improve patient and allograft longevity by facilitating a personalized and precision approach to post-HT care. The following article is a contemporary review of the current and future opportunities to leverage omics technologies, including genomics, transcriptomics, proteomics, and metabolomics in the field of HT.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Corazón / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Curr Heart Fail Rep Asunto de la revista: CARDIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Trasplante de Corazón / Insuficiencia Cardíaca Límite: Humans Idioma: En Revista: Curr Heart Fail Rep Asunto de la revista: CARDIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos